Legal & General Group Plc Makes New Investment in Ralliant Corporation $RAL

Legal & General Group Plc purchased a new stake in Ralliant Corporation (NYSE:RAL) in the second quarter, HoldingsChannel reports. The institutional investor purchased 249,207 shares of the company’s stock, valued at approximately $18,349,000.

Several other institutional investors also recently modified their holdings of the company. Cetera Investment Advisers bought a new stake in shares of Ralliant in the 2nd quarter valued at about $700,000. Russell Investments Group Ltd. bought a new position in Ralliant during the second quarter worth about $1,465,000. EverSource Wealth Advisors LLC acquired a new position in Ralliant during the second quarter worth approximately $39,000. First Trust Advisors LP acquired a new position in Ralliant during the second quarter worth approximately $2,013,000. Finally, Federated Hermes Inc. bought a new stake in Ralliant in the second quarter valued at approximately $326,000.

Insider Transactions at Ralliant

In other Ralliant news, SVP Karen M. Bick sold 6,062 shares of the stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $72.00, for a total transaction of $436,464.00. Following the transaction, the senior vice president owned 31,668 shares in the company, valued at $2,280,096. This represents a 16.07% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Tamara S. Newcombe sold 12,936 shares of the firm’s stock in a transaction that occurred on Friday, August 14th. The stock was sold at an average price of $71.79, for a total transaction of $928,675.44. Following the transaction, the chief executive officer directly owned 251,967 shares in the company, valued at $18,088,710.93. This represents a 4.88% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.42% of the stock is currently owned by company insiders.

Ralliant Stock Performance

RAL opened at $61.65 on Monday. The business has a fifty day simple moving average of $68.40 and a 200 day simple moving average of $56.53. The company has a market capitalization of $6.82 billion, a PE ratio of -5.68, a price-to-earnings-growth ratio of 2.29 and a beta of 1.61. Ralliant Corporation has a 1 year low of $37.27 and a 1 year high of $75.41. The company has a debt-to-equity ratio of 0.75, a current ratio of 1.52 and a quick ratio of 1.00.

Ralliant (NYSE:RAL) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.68 earnings per share for the quarter, topping the consensus estimate of $0.63 by $0.05. Ralliant had a positive return on equity of 14.97% and a negative net margin of 56.38%.The firm had revenue of $567.80 million for the quarter. Ralliant has set its FY 2026 guidance at 2.760-2.900 EPS and its Q3 2026 guidance at 0.720-0.780 EPS. Research analysts expect that Ralliant Corporation will post 2.87 EPS for the current year.

Ralliant Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, September 23rd. Investors of record on Tuesday, September 8th will be given a dividend of $0.05 per share. This represents a $0.20 dividend on an annualized basis and a yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 8th. Ralliant’s dividend payout ratio (DPR) is currently -1.84%.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. Zacks Research upgraded Ralliant from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, June 30th. Citigroup lifted their price objective on shares of Ralliant from $81.00 to $82.00 and gave the stock a “buy” rating in a research report on Friday, July 31st. Wall Street Zen downgraded shares of Ralliant from a “strong-buy” rating to a “buy” rating in a report on Sunday. Morgan Stanley increased their price objective on shares of Ralliant from $68.00 to $85.00 and gave the company an “overweight” rating in a research report on Tuesday, June 23rd. Finally, Vertical Research downgraded shares of Ralliant from a “buy” rating to a “hold” rating and set a $65.00 target price for the company. in a report on Wednesday, May 27th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $75.70.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.